Melatonina

Condiciones de salud que Melatonina puede ayudar a apoyar.

• AbrasionesCientífico

  Melatonin has been studied in multiple RCTs for GERD. A published PMC RCT (n=60) concluded oral melatonin is a promising therapeutic agent for GERD, significantly relieving heartburn and epigastric pain. A registered double-blind trial (NCT00564590, n=150) compared melatonin to PPIs with 24-hour esophageal pH monitoring. Melatonin reduces nitric oxide synthesis (reducing LES relaxation) and exerts antioxidant/anti-inflammatory effects on the esophageal mucosa.

• HipocondríaCientífico

  Melatonin is a direct free radical scavenger acting on both oxygen- and nitrogen-based reactive species, and also indirectly upregulates antioxidant enzymes. A meta-analysis of 16 clinical trials demonstrated significant increases in total antioxidant capacity (TAC) and reductions in malondialdehyde (MDA), a marker of lipid peroxidation. Effects are most consistent in trials lasting up to 8 weeks.

• Acidez EstomacalCientífico

  Melatonin has demonstrated anxiolytic effects in multiple clinical contexts, particularly preoperative anxiety and sleep-related anxiety. A review in PMC documents its clinical anxiolytic action across several conditions. It acts via MT1 and MT2 melatonin receptors and modulates the HPA axis and circadian rhythm-related anxiety pathways. It is widely reviewed in mainstream clinical pharmacology for this indication.

• Trastornos Inflamatorios del IntestinoCientífico

  Melatonin is well-documented for treating sleep-onset insomnia in children with ADHD on stimulant medications, with multiple RCTs and reviews supporting its efficacy for sleep, though evidence for direct reduction of core ADHD symptoms (inattention/hyperactivity) is minimal. The PMC4170184 review (NIH) and NCCIH both recognize melatonin's role in ADHD-related sleep management.

• Contaminación ElectromagnéticaCientífico

  Melatonin has immunomodulatory properties and has been studied in autoimmune diseases including SLE, RA, and multiple sclerosis. It modulates Th17/Treg balance, reduces oxidative stress, and exhibits anti-inflammatory effects. Clinical data show lower melatonin levels in SLE patients, and supplementation trials demonstrate reductions in disease activity markers.

• HipotensiónCientífico

  Controlled-release melatonin has been cited by multiple authoritative reviews as having clinical evidence for blood pressure reduction. A 2025 dose-response meta-analysis confirmed melatonin supplementation significantly reduced systolic blood pressure (WMD: −2.34 mmHg). It modulates circadian blood pressure patterns and reduces sympathetic activity.

• Manchas de la edadCientífico

  Clinical RCTs indicate melatonin supplementation may increase bone mineral density, particularly at the femoral neck, in postmenopausal women with osteopenia. Mechanistically, melatonin promotes osteoblast differentiation and suppresses osteoclastogenesis via MT2 receptors. Evidence is promising but limited by small trial numbers and high heterogeneity.

• AmenorreaCientífico

  Melatonin is an endogenous pineal hormone that regulates the circadian sleep-wake cycle. Multiple meta-analyses and a Cochrane systematic review confirm it reduces sleep onset latency and improves sleep quality. By facilitating pre-sleep calm and sleep initiation, it supports overall relaxation. Effective doses are 0.5–5 mg taken 30–60 minutes before bedtime. Approved as a prescription medicine in the EU for insomnia in adults over 55.

• ApatíaCientífico

  Melatonin is the most evidence-backed supplement for children's sleep disorders. Multiple RCTs and systematic reviews demonstrate it reduces sleep-onset latency and increases total sleep time in children with neurodevelopmental disorders, ADHD, autism spectrum disorder, and delayed sleep-wake phase disorder. A 2023 Lancet meta-analysis (9 studies) found melatonin reduced sleep latency by approximately 15 minutes and increased total sleep time by approximately 19 minutes in pediatric populations.

• ApendicitisCientífico

  A systematic review and meta-analysis of 31 clinical trials (1,517 participants) found melatonin supplementation significantly reduced pro-inflammatory cytokines including IL-1, IL-6, and IL-8. In the late phase of inflammation, melatonin downregulates inflammatory mediators and reduces oxidative stress. Evidence spans diverse populations and disease states.

• ImpétigoCientífico

  Melatonin has antinociceptive and anti-inflammatory properties relevant to chronic pain, particularly fibromyalgia and migraine. Clinical trials show melatonin reduces pain and improves sleep in fibromyalgia. It modulates opioid, GABA, and 5-HT receptors and is listed among supplements with the best evidence for fibromyalgia chronic pain management.

• Apetito (deficiente)Científico

  Melatonin is the primary endogenous chronobiotic hormone produced by the pineal gland. Exogenous melatonin has strong RCT evidence for phase-shifting the circadian clock, treating delayed sleep phase syndrome, jet lag, and free-running circadian rhythm in blind individuals. A 2022 systematic review and meta-analysis confirmed phase-advancing effects and sleep consolidation across populations.

• IncontinenciaCientífico

  Melatonin, an endogenous pineal hormone that declines with age, has been studied in clinical trials for its potential to slow cognitive decline in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Evidence from multiple RCTs and meta-analyses suggests modest cognitive benefits, particularly in MCI patients and those with comorbid sleep disturbance, though results in more advanced dementia remain inconsistent. Its proposed mechanisms include antioxidant activity, inhibition of amyloid-beta aggregation, anti-tau effects, and circadian rhythm restoration. Larger, longer-duration trials are still needed to firmly establish efficacy and optimal dosing.

• Infecciones OcularesCientífico

  Melatonin is a pineal hormone that crosses the blood-brain barrier and has documented neuroprotective properties including antioxidant, anti-inflammatory, and sleep-regulatory effects highly relevant to concussion recovery. A 2018 PMC review synthesized evidence for melatonin after TBI, finding it reduces brain swelling, improves cognition, and alleviates neurological deficits in animal models. A 2024 Nutrients narrative review and a 2025 PubMed review both list melatonin as a key supplement under active clinical investigation for concussion/mTBI management, particularly for post-TBI sleep disruption.

• Ojos (manchas ante los ojos)Científico

  Melatonin has been studied for its ability to inhibit enzymes involved in cortisol biosynthesis in the adrenal glands, making it relevant to Cushing's disease management. Studies show melatonin circadian secretion is significantly lower in patients with pituitary- or adrenal-dependent Cushing's syndrome compared to healthy controls. Research (Pawlikowski et al., 2002) demonstrated that nightly administration of 2 mg melatonin increased the DHEA-S-to-cortisol ratio after 6 months. University of Tennessee veterinary studies found melatonin combined with lignans reduces adrenal steroid concentrations in Cushing's cases.

• Trastorno por Déficit de AtenciónCientífico

  Melatonin addresses circadian rhythm dysregulation, a recognized feature of depression. Clinical trials show melatonin improves sleep disturbance in depression and shows mild antidepressant effects. A 2022 Dove Medical Press review confirmed melatonin among supplements significantly reducing depression scores. It has mixed evidence per a 2025 scoping review.

• DesmayoCientífico

  Melatonin is a neuroendocrine hormone with antioxidant, analgesic, and anti-inflammatory properties that has been evaluated in endometriosis RCTs. A landmark phase II RCT (2013) found 10 mg/night significantly reduced endometriosis-associated chronic pelvic pain by approximately 40% and reduced analgesic use by approximately 80% over two months. A subsequent RCT yielded mixed results.

• Antojos de grasaCientífico

  Melatonin has been investigated as adjunctive therapy for epilepsy in multiple small clinical trials. A 2023 randomized double-blind placebo-controlled trial found melatonin significantly reduced the severity of epileptic seizures. Mechanistically, melatonin modulates neuronal activity by reducing glutamatergic and enhancing GABAergic neurotransmission, and its metabolite kynurenic acid is an endogenous anticonvulsant.

• Sangrado (externo)Científico

  Melatonin, a potent free-radical scavenger concentrated in follicular fluid, improves oocyte and embryo quality when combined with myo-inositol or vitamin D in IVF settings. Clinical trials show benefits in clinical pregnancy rates. Women with PCOS have lower follicular melatonin, and supplementation partially corrects this deficit.

• Metabolismo de grasas (deficiente)Científico

  FM patients have documented lower nocturnal melatonin secretion. A 2019 systematic review of four controlled and uncontrolled studies in 98 FM patients concluded all studies reported positive effects of melatonin on FM symptoms including pain, sleep, fatigue, and tender point count, with no major adverse events. A 2010 double-blind placebo-controlled RCT in 101 FM patients found melatonin alone or combined with fluoxetine significantly reduced total FIQ scores.

• InfecciónCientífico

  Melatonin may have a role in gallstone disease prevention or treatment due to its anti-inflammatory, free-radical-scavenging properties, and beneficial effects on gallbladder muscle tone and motility. Life Extension's gallstones protocol (citing Pozo 2010 and Koppisetti studies via PubMed) includes melatonin among natural interventions that may reduce gallstone formation risk by improving gallbladder emptying and reducing oxidative stress in biliary epithelium.

• Tumores grasos o depósitosCientífico

  Melatonin has substantial research supporting both IOP regulation and neuroprotection in glaucoma. It activates MT receptors to modulate aqueous humor dynamics, and protects RGCs against oxidative stress, mitochondrial dysfunction, and apoptosis. A 2025 comprehensive PubMed/Medline review identified melatonin among nutraceuticals with compelling glaucoma evidence.

• ForúnculosCientífico

  Melatonin, the pineal gland hormone, is documented in multiple clinical studies to stimulate GH secretion in humans. A 1993 Clinical Endocrinology RCT (Valcavi et al.) showed oral melatonin (10 mg) approximately doubled GHRH-stimulated GH release and increased basal GH through pathways involving somatostatin suppression. Exogenous oral melatonin at both 0.5 mg and 5.0 mg has been shown to produce significant increases in plasma GH concentrations.

• Bultos en el SenoCientífico

  Melatonin applied topically or systemically as an adjunct to non-surgical periodontal therapy has been shown to reduce periodontal pocket depth in multiple RCTs. A 2021 meta-analysis of two RCTs found that combined non-surgical periodontal therapy plus melatonin significantly reduced pocket depths vs. treatment alone. Its antioxidant and anti-inflammatory properties modulate oxidative stress in periodontal tissues.

• Huesos RotosCientífico

  Melatonin has been studied in multiple RCTs for migraine prophylaxis. A double-blind RCT (n=60, 3 mg/night plus propranolol) showed significant reductions in attack frequency, duration, and severity. The 2024 Current Pain and Headache Reports review recommends melatonin weakly for migraineurs with sleep problems, citing very low-certainty evidence.

• BronquitisCientífico

  Melatonin is a pineal hormone with potent antioxidant properties whose production declines dramatically with age. It regulates circadian rhythms (disrupted in aging), protects mitochondria from oxidative damage, reduces inflammaging, and has demonstrated anti-aging effects in multiple model organisms. Human clinical trials confirm melatonin's benefits for sleep quality, cognitive aging, and oxidative biomarkers in older adults.

• BulimiaCientífico

  Melatonin is a potent antioxidant hormone studied for prevention of age-related hearing loss (presbycusis) and noise-induced ototoxicity. Animal studies in C57BL/6J mice (12-month intervention) confirmed melatonin prevented cochlear hair cell degeneration. Melatonin has been used in combination with CoQ10 in clinical pilot trials showing protection against cisplatin-induced hearing damage.

• JuanetesCientífico

  Clinical and epidemiological evidence links lower endogenous melatonin levels with increased cardiovascular disease risk, including hypertension and heart failure. RCTs show melatonin can reduce nocturnal blood pressure and may modulate markers associated with ischemia-reperfusion injury. However, large-scale clinical outcome trials remain lacking.

• Cáncer (prevención)Científico

  Melatonin has been evaluated in clinical trials for menopausal hot flashes via GABAergic and thermoregulatory mechanisms. One double-blind RCT found 3 mg melatonin produced significant improvement in vasomotor symptoms in women with severe climacteric symptoms. A combination RCT (soy isoflavones + 8-prenylnaringenin + melatonin) also demonstrated improved hot flashes. Evidence is preliminary.

• PulgasCientífico

  Melatonin has meta-analytic evidence for IBS. A 2022 meta-analysis (4 RCTs, 115 participants) found exogenous melatonin significantly improved overall IBS severity versus placebo (Hedges' g=0.746, p<0.001), IBS pain severity (p<0.001), and quality of life (p=0.007). A 2023 RCT in 136 ROME IV–diagnosed IBS patients found significant improvement in IBS score, GI symptoms, and quality of life with 6 mg melatonin daily for 8 weeks.

• Debilidad CapilarCientífico

  Melatonin is a pineal hormone that regulates circadian rhythms and is one of the most studied natural sleep aids. Multiple meta-analyses show it moderately reduces sleep onset latency and increases total sleep time in insomnia patients. Effects are most consistent in older adults and those with comorbid or circadian-rhythm-related insomnia.

• Enfermedad CardiovascularCientífico

  Melatonin has the strongest scientific evidence base for jet lag among all supplements. A Cochrane systematic review of ten randomized trials found that 8 of 10 studies showed melatonin taken close to destination bedtime decreased jet lag from flights crossing five or more time zones. It acts as a chronobiotic by binding MT1/MT2 receptors in the suprachiasmatic nucleus to shift circadian phase and promote sleep onset at the new local time. Doses of 0.5–5 mg taken at the target bedtime at the destination for 2–5 nights are most consistently supported.

• CelulitisCientífico

  Animal studies show pharmacologic melatonin treatment significantly reduces plasma ghrelin concentrations and modulates the inverse leptin–ghrelin relationship. Human research confirms that circadian disruption (light at night, sleep restriction) lowers leptin and raises ghrelin, with melatonin's circadian role proposed to buffer these changes. A 2025 pilot RCT protocol specifically targets melatonin's effect on plasma ghrelin in overweight females.

• GangrenaCientífico

  Melatonin is an endogenous antioxidant hormone produced in the pineal gland that also has ocular production and multiple melatonin receptors in the eye. A small clinical study of approximately 100 AMD patients found that supplementation with melatonin (combined with zinc and selenium) prevented further vision loss and reduced pathological macular changes. Low melatonin levels have been correlated with AMD. A 2024 PMC narrative review identifies melatonin as a promising emerging AMD therapy.

• Gas e HinchazónCientífico

  Topical melatonin (0.1% solution) exhibits antioxidant and mild anti-androgenic properties. Five clinical studies (Fischer et al., Int J Trichology, 2012) showed positive effects on hair density and anagen phase in men and women with AGA. A 2025 network meta-analysis ranked topical melatonin as the highest-performing non-conventional AGA treatment after 5% minoxidil (SUCRA=61.9%).

• CóleraCientífico

  Melatonin levels decline with aging and during menopause, contributing to the sleep disturbances that affect up to 60% of menopausal women. Multiple RCTs support melatonin supplementation for improving sleep quality in postmenopausal women. It is listed as a recognized menopausal ingredient in authoritative ingredient databases.

• GlaucomaCientífico

  Melatonin has been studied in multiple RCTs for migraine prophylaxis, with most showing reductions in attack frequency, duration, and severity. A 2024 Nutraceuticals review characterized melatonin as weakly recommended, particularly for migraineurs with comorbid sleep disturbances, though evidence certainty is rated very low.

• Circulación (deficiente)Científico

  Melatonin concentrates in mitochondria and functions as a direct mitochondrial antioxidant, scavenging ROS and protecting against mitochondrial membrane permeabilization. It activates SIRT3 and stimulates mitochondrial biogenesis. Clinical reviews identify melatonin as a micronutrient supporting ETC function, and it has been studied in mitochondrial disease contexts.

• GotaCientífico

  Melatonin, the pineal hormone regulating circadian sleep-wake cycles, is used in narcolepsy management primarily to improve disrupted nighttime sleep—a common comorbid symptom. Clinical literature indicates melatonin can slightly improve nighttime sleep consolidation in narcolepsy patients but does not address the core orexin deficiency, daytime sleep attacks, or cataplexy. Integrative medicine reviews cite melatonin as a supportive adjunct for narcolepsy's circadian and sleep fragmentation components.

• Infección (bacteriana)Científico

  Melatonin is a pineal hormone that directly promotes osteoblastogenesis and suppresses osteoclastogenesis via MT2 receptors in mesenchymal stem cells and bone cells. Multiple reviews confirm melatonin supplementation improves bone mass in rodent osteoporosis models, and several clinical trials indicate bone mass-conserving effects in aging and postmenopausal osteoporosis. It also improves gut ecology to support bone metabolism.

• Duelo y TristezaCientífico

  Melatonin, produced endogenously from L-tryptophan, has receptors in pancreatic tissue and has demonstrated protective effects against acute pancreatitis in numerous experimental studies and clinical observations. It reduces ROS/RNS, preserves antioxidant enzyme activity, decreases TNF-α, improves pancreatic blood flow, and reduces apoptosis and necrosis. Clinical reviews indicate potential for prevention of post-ERCP pancreatitis.

• Cabello (encanecimiento)Científico

  Melatonin, the pineal hormone with potent antioxidant and neuroprotective properties, is often studied in Parkinson's disease. Sleep disturbances are among the most common non-motor symptoms of PD, and melatonin has evidence for improving sleep in PD patients. Additionally, preclinical studies demonstrate it protects dopaminergic neurons from oxidative damage.

• Cabello (pérdida o adelgazamiento)Científico

  Melatonin has been evaluated in multiple RCTs for PCOS, showing improvements in oocyte quality, pregnancy rates in IUI, reduced testosterone, and anti-oxidant benefits. It is listed in major evidence reviews as one of the evidence-supported formulations for PCOS.

• Congestión (bronquial)Científico

  Melatonin levels decline during perimenopause, paralleling worsening sleep. A review found doses above 3 mg improved common menopausal symptoms including hot flashes, insomnia, mood changes, and sexual disorders. An RCT in perimenopausal women taking 3 mg nightly for 6 months showed improved sleep quality and tolerability.

• ConjuntivitisCientífico

  Beyond its role as a sleep hormone, melatonin has documented anti-inflammatory, antioxidant, and immunomodulatory properties relevant to post-illness recovery. A 2020 MDPI review cited evidence for melatonin aiding recovery from viral infections, and it was listed alongside adaptogens for COVID convalescence.

• Enfermedades ContagiosasCientífico

  Melatonin is specifically cited in multiple post-COVID clinical reviews for managing brain fog, pain, sleep dysregulation, oxidative stress, and immune dysregulation in long COVID. It reduces inflammatory cytokines (CRP, TNF, IL-6) as confirmed in a 2021 systematic review overview. The VA Long COVID guide and multiple integrative medicine reviews recommend melatonin for post-viral sleep and cognitive recovery.

• Fibrilación cardíaca o palpitacionesCientífico

  Melatonin deficiency has been extensively studied in adolescent idiopathic scoliosis (AIS) pathogenesis, with low melatonin levels correlating with progressive scoliosis. An animal model (pinealectomized chickens) established a scoliosis-inducing effect of melatonin deficiency. A clinical study of 40 AIS patients showed oral melatonin (3 mg) stabilized scoliosis in 12 of 16 patients with low melatonin levels. A randomized Romanian trial combining melatonin (1.5 mg/day) with calcium and vitamin D showed positive effects on curve progression.

• Válvulas CardíacasCientífico

  Melatonin is a pineal hormone regulating circadian rhythms and sleep-wake cycles, both disrupted in SAD. The duration of nocturnal melatonin secretion increases in winter, and abnormal melatonin secretion has been observed in SAD patients. NCCIH specifically lists melatonin among complementary approaches reviewed for SAD, noting limited evidence that it improves sleep in SAD patients. It is also hypothesized as a chemical mediator of photoperiodic effects on seasonal mood.

• HemorroidesCientífico

  Melatonin secretion is disrupted in OSA patients, with studies showing a delayed or blunted nocturnal peak. A randomized double-blind placebo-controlled trial in patients with comorbid OSA and insomnia (COMISA) demonstrated that melatonin improved sleep quality and daytime sleepiness. Research also indicates melatonin-based medications may benefit sleep quality in OSA populations with minimal adverse respiratory effects.

• Calambres (menstruales)Científico

  Melatonin is an endogenous pineal hormone with the most robust scientific evidence among natural compounds for improving sleep maintenance. Multiple meta-analyses of RCTs demonstrate significant increases in sleep efficiency and total sleep time. A 2005 meta-analysis of 17 RCTs found melatonin increased sleep efficiency by 2.2% and total sleep duration by 12.8 minutes versus placebo. A 2013 meta-analysis of 19 RCTs confirmed improvements in total sleep time and overall sleep quality; effects do not dissipate with continued use.

• Calambres y EspasmosCientífico

  Melatonin is the most extensively studied natural sleep-onset agent. Multiple meta-analyses of RCTs confirm it reduces sleep onset latency (SOL) by approximately 7–10 minutes on average, with the largest effects seen in delayed sleep phase disorder (up to ~39 minutes SOL reduction). A dose-response meta-analysis of 26 RCTs found benefits peak at around 4 mg/day.

• Enfermedad de CrohnCientífico

  Melatonin is the primary endogenous regulator of the sleep-wake cycle, produced by the pineal gland in response to darkness. Multiple systematic reviews and meta-analyses of RCTs confirm it reduces sleep onset latency, increases total sleep time, and improves subjective sleep quality as measured by the PSQI. Prolonged-release melatonin (2 mg) is approved in the EU for primary insomnia in adults over 55. A 2021 meta-analysis (PubMed PMID 33417003) found a significant effect on PSQI score (WMD −1.24; 95% CI −1.77 to −0.71).

• CrupCientífico

  Melatonin has been studied in patients with obstructive sleep apnea (OSA), the primary disorder underlying most snoring. A 2024 randomized double-blind placebo-controlled trial found 10 mg melatonin improved sleep latency, reduced mid-night wakeups, and enhanced sleep quality in OSA patients. Melatonin secretion is significantly altered in approximately 25% of OSA patients. It has also been included in patented snoring treatment formulations alongside L-tryptophan.

• Fibrosis QuísticaCientífico

  An endogenous pineal hormone with documented anxiolytic and HPA axis-modulating actions. Clinical and preclinical evidence shows melatonin counteracts HPA hyperactivation, reduces stress-induced neuroinflammation, and demonstrates anxiolytic effects in various clinical conditions. Used to mitigate physiological stress responses.

• HepatitisCientífico

  Melatonin at 3 mg nightly has been evaluated in multiple clinical trials for tinnitus. A 2024 meta-analysis of six prospective studies (n=176) found a statistically significant weighted mean reduction in Tinnitus Handicap Inventory (THI) scores. Benefits are most evident in patients with severe or bilateral tinnitus and in those with sleep disturbance related to tinnitus.

Sistemas corporales que Melatonina puede ayudar a apoyar.

• No hay sistemas corporales disponibles.